• In April 2026, ANI Pharmaceuticals launched three U.S. generics, Carbamazepine Extended-Release Capsules, Pimozide Tablets, and Isosorbide Mononitrate Tablets, targeting reference drugs Carbatrol, Orap, and Monoket, in markets with combined annual sales of about US$68.10 million based on IQVIA data.
• Away from generics, the publication of Phase 4 NEW DAY trial results for ILUVIEN in Ophthalmology underscores ANI’s focus on evidence generation and its efforts to support adoption of its retina portfolio despite meaningful safety monitoring requirements.
• We’ll now examine how this fresh wave of generic launches, especially Carbamazepine ER, may influence ANI Pharmaceuticals’ broader investment narrative.

Find 63 companies with promising cash flow potential yet trading below their fair value.

ANI Pharmaceuticals Investment Narrative Recap

To own ANI Pharmaceuticals, you need to believe it can balance a growing rare disease and retina franchise with a still-important generics engine, while managing payer pressure and competition. The April 2026 generic launches modestly support near term revenue ambitions, but do not materially change the key near term swing factors: execution in Cortrophin Gel and retina access, and the risk that first to market generic tailwinds fade faster than expected.

Among the recent updates, the launch of Carbamazepine Extended Release Capsules stands out, given its reference market of about US$65,000,000 in annual U.S. sales based on IQVIA data. For investors tracking catalysts, Carbamazepine ER, alongside Pimozide and Isosorbide Mononitrate, helps illustrate whether ANI can consistently replenish higher margin generic contributions as older exclusivity periods roll off and competition intensifies.

Yet behind this progress, investors should be aware that payer pressure on Cortrophin Gel and retina access could still...

ANI Pharmaceuticals’ narrative projects $1.3 billion revenue and $191.7 million earnings by 2029. This implies an earnings increase from today’s level to reach the 2029 consensus forecast.

Uncover how ANI Pharmaceuticals' forecasts yield a $110.62 fair value, a 35% upside to its current price.

Exploring Other Perspectives

Before this news, the most optimistic analysts were framing Cortrophin and retina upside very differently, assuming revenue could reach about US$1.2 billion and earnings nearly US$100 million, so if you lean bullish you may see these new generic launches as further support while if you focus on concentration risk in a few brands, you might view them as only a small offset and a reason to compare several viewpoints before deciding how ANI fits your portfolio.

Explore 7 other fair value estimates on ANI Pharmaceuticals - why the stock might be worth just $90.00!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your ANI Pharmaceuticals research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision.
• Our free ANI Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ANI Pharmaceuticals' overall financial health at a glance.

Interested In Other Possibilities?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Outshine the giants: these 19 early-stage AI stocks could fund your retirement.
• AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The latest GPUs need a type of rare earth metal called Terbium and there are only 31 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.